Serum IGF-I and IGFBP-3 Concentrations in Children with Cancer: Comparisons with Normal Children.
- Author:
Kyung In HAN
1
;
A Rum HWANG
;
So Hyun PARK
;
Min Ho JUNG
;
Nac Gyun CHUNG
;
Byung Kyu SUH
;
Byung Churl LEE
Author Information
1. Department of Pediatrics, College of Medicine, The Catholic University of Korea, Seoul, Korea. suhbk@catholic.ac.kr
- Publication Type:Original Article
- Keywords:
Cancers;
IGF-I;
IGFBP-3;
Chemotherapy;
Radiotherapy
- MeSH:
Body Weight;
Child*;
Drug Therapy;
Humans;
Insulin-Like Growth Factor Binding Protein 3*;
Insulin-Like Growth Factor I*;
Leukemia;
Molar;
Radiotherapy
- From:Journal of Korean Society of Pediatric Endocrinology
2006;11(1):33-39
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: Since insulin-like growth factor-I (IGF-I) and insulin-like growth factor binding protein-3 (IGFBP-3) are often used as markers for growth assessment, we compared the serum IGF-I and IGFBP-3 levels in children diagnosed with cancer with those in the healthy children. METHODS: Forty-nine children who were diagnosed with cancer and treated with radiotherapy or chemotherapy were enrolled in the study. Sixty-four healthy children without any medical problems were enrolled as controls. Height, weight, body mass index (BMI), height standard deviation score (HTSDS), serum IGF-I, serum IGFBP-3 and molar ratio of IGF-I/IGFBP-3 were compared between the two groups. RESULTS: The mean age of children in the control group was 9.3+/-2.9 years and that of children in the cancer group was 8.8+/-3.3 years. There were no significant differences in mean height, weight, BMI and HT SDS between in the two group. Serum IGF-I levels increased with age in both groups, and the mean level of the control group was significantly higher than that of the cancer group. The mean serum level of IGFBP-3 in the control group was higher than that of the cancer group. IGF-I/IGFBP-3 molar ratio also increased with age in both groups and the mean level of molar ratio of the control group was higher than that of the cancer group. IGF-I, IGFBP-3, and IGF-I/IGFBP-3 molar ratio in the leukemia group and the solid tumor group were not significantly different. Mean age, IGF-I and IGFBP-3 concentrations in the chemotherapy group were higher than those in the chemotherapy and radiation therapy group. CONCLUSION: The serum levels of IGF-I and IGFBP-3 in children diagnosed with cancer, treated with radiotherapy or chemotherapy, were lower than those of the control group. In conclusion, the serum levels of IGF-I and IGFBP-3 can possibly be used as early markers of growth assessment in children with cancer treatment.
